Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes
A partir de données portant sur 369 échantillons tumoraux prélevés sur des patients atteints d'un carcinome hépatocellulaire, cette étude identifie trois sous-types de la maladie exhibant des différences significatives dans des voies de signalisation métabolique
Hepatocellular carcinoma (HCC) is a heterogeneous and deadly form of liver cancer. Here, we stratified and characterized HCC tumors by applying graph and control theory concepts to the topology of genome-scale metabolic networks. We identified three HCC subtypes with distinct differences in metabolic and signaling pathways and clinical survival and validated our results by performing additional experiments. We further identified HCC subtype-specific genes pivotal in controlling the entire metabolism and discovered genes that can be targeted for development of efficient treatment strategies for specific HCC subtypes. Our systems-level analyses provided a systematic way for characterization of HCC subtypes and identification of drug targets for effective treatment of HCC patients.
Hepatocellular carcinoma (HCC) is one of the most frequent forms of liver cancer, and effective treatment methods are limited due to tumor heterogeneity. There is a great need for comprehensive approaches to stratify HCC patients, gain biological insights into subtypes, and ultimately identify effective therapeutic targets. We stratified HCC patients and characterized each subtype using transcriptomics data, genome-scale metabolic networks and network topology/controllability analysis. This comprehensive systems-level analysis identified three distinct subtypes with substantial differences in metabolic and signaling pathways reflecting at genomic, transcriptomic, and proteomic levels. These subtypes showed large differences in clinical survival associated with altered kynurenine metabolism, WNT/β-catenin–associated lipid metabolism, and PI3K/AKT/mTOR signaling. Integrative analyses indicated that the three subtypes rely on alternative enzymes (e.g., ACSS1/ACSS2/ACSS3, PKM/PKLR, ALDOB/ALDOA, MTHFD1L/MTHFD2/MTHFD1) to catalyze the same reactions. Based on systems-level analysis, we identified 8 to 28 subtype-specific genes with pivotal roles in controlling the metabolic network and predicted that these genes may be targeted for development of treatment strategies for HCC subtypes by performing in silico analysis. To validate our predictions, we performed experiments using HepG2 cells under normoxic and hypoxic conditions and observed opposite expression patterns between genes expressed in high/moderate/low-survival tumor groups in response to hypoxia, reflecting activated hypoxic behavior in patients with poor survival. In conclusion, our analyses showed that the heterogeneous HCC tumors can be stratified using a metabolic network-driven approach, which may also be applied to other cancer types, and this stratification may have clinical implications to drive the development of precision medicine.
Proceedings of the National Academy of Sciences , résumé, 2017